enVVeno Medical Announces Reverse Stock Split

enVVeno Medical (NASDAQ:NVNO) announced a reverse stock split at a 1-for-35 ratio, effective 12:01 a.m. ET on January 20, 2026.

Rhea-AI Summary

enVVeno Medical (NASDAQ:NVNO) announced a reverse stock split at a 1-for-35 ratio, effective 12:01 a.m. ET on January 20, 2026. Post-split trading on The Nasdaq Capital Market under the existing symbol NVNO will begin on January 20, 2026, and the company will use a new CUSIP 29415J205.

Shareholders approved the Reverse Stock Split at the annual meeting on December 11, 2025. The split will combine every 35 pre-split shares into one post-split share, reducing outstanding common stock from approximately 22.9 million to approximately 655 thousand. No fractional shares will be issued; cash will be paid in lieu of fractions. Equity awards and warrants will be adjusted accordingly.

Positive

• Reverse split reduces outstanding shares from ~22.9M to ~655K
• Effective date set for January 20, 2026, providing clear timing
• New CUSIP 29415J205 and post-split trading under NVNO confirmed

Negative

• Company will pay cash in lieu of fractional shares, creating small cash outflows
• Outstanding equity awards and warrants will be adjusted, altering investor positions

Argus Jan 15 session

-13.18% close to close Open Argus

Details

News Market Reaction – NVNO

On Jan 15, the day this news came out, NVNO closed 13.18% below the previous close.

Data tracked by StockTitan Argus for the Jan 15 session.

Market Context

On Jan 15, the day this news came out, the stock closed 13.2% below the previous close. A negative r...

Analysis

On Jan 15, the day this news came out, the stock closed 13.2% below the previous close. A negative reaction despite the structural nature of the announced 1-for-35 reverse stock split would fit a pattern of volatility around corporate and regulatory events. Prior headlines produced moves from -6.41% to +15.89%, even when news was largely informational. With shares previously at $0.3611, far below the $2.19 200-day MA and 93.57% under the 52-week high, past weakness and sensitivity to news could have amplified selling as investors reassessed dilution mechanics and post-split liquidity.

Key Figures

Reverse split ratio: 1-for-35 Effective date & time: 12:01 a.m. ET, January 20, 2026 New CUSIP: 29415J205 +5 more

Reverse split ratio

1-for-35

Approved reverse stock split of common shares

Effective date & time

12:01 a.m. ET, January 20, 2026

Reverse stock split effective time

New CUSIP

29415J205

CUSIP for post-split common stock

Par value

$0.00001 per share

Par value unchanged after reverse split

Pre-split shares

approximately 22.9 million

Outstanding common stock before reverse split

Post-split shares

approximately 655 thousand

Outstanding common stock after reverse split

Transfer agent phone (toll free)

(877) 248-6417

Equiniti contact for stockholders

Transfer agent phone

(718) 921-8317

Equiniti contact for stockholders

Historical Context

5 past events · Latest: Nov 26

5 events

1. Nov 26

   Investor presentation

   24h Move

   -6.4%

   Announcement of CEO participation in virtual investor segment.

2. Nov 13

   Regulatory decision

   24h Move

   -5.2%

   Unfavorable FDA supervisory appeal decision upholding not-approvable letter.

3. Oct 31

   Earnings and update

   24h Move

   +1.1%

   Q3 2025 results with cash runway into 2027 and reduced net loss.

4. Sep 26

   Regulatory discussion

   24h Move

   +1.2%

   CEO discussion of supervisory appeal request following not-approvable letter.

5. Sep 15

   Regulatory update

   24h Move

   +15.9%

   Plan to file supervisory appeal challenging FDA not-approvable letter for VenoValve.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

reverse stock split, cusip, par value, equity awards, +3 more

7 terms

reverse stock split financial

"approved a reverse stock split of its shares of common stock at a ratio"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

cusip technical

"common stock will also commence trading under a new CUSIP number 29415J205."

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

par value financial

"with no change to the par value of $0.00001 per share."

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

equity awards financial

"shares and exercise prices, as applicable, underlying the Company's outstanding equity awards"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

warrants financial

"underlying the Company's outstanding equity awards and warrants will also be adjusted"

Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.

View in glossary

transfer agent financial

"The Company's transfer agent, Equiniti Trust Company, LLC, will provide stockholders"

A transfer agent is a financial service that keeps the official record of who owns a company's shares, handles the buying and selling of those shares on paper or electronically, and issues or cancels stock certificates. Think of it as the company’s records keeper and mailroom combined—investors rely on it to make sure dividends, shareholder mailings, ownership changes, and proxy voting are processed accurately and securely, which protects ownership rights and helps prevent errors or fraud.

book-entry technical

"holding pre-split shares of the Company's common stock electronically in book-entry form"

A book-entry is an electronic record that shows who legally owns a share, bond or other security instead of a paper certificate. Think of it like a bank ledger entry that tracks ownership and transfers; it makes buying, selling, dividend payments and ownership checks faster, cheaper and less risky for investors because nothing physical needs to be moved or stored.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, CA / ACCESS Newswire / January 15, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1 for 35 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern time on January 20, 2026 and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on January 20, 2026 under the Company's existing trading symbol "NVNO". At such time, the Company's common stock will also commence trading under a new CUSIP number 29415J205.

"The Reverse Stock Split, which was approved by stockholders at the Company's annual meeting on December 11, 2025, is an important first step in a multi-part plan for 2026 that we expect will create value for shareholders and reestablish our roadmap for enVVeno medical to become the preeminent company for treating deep venous disease," commented Robert Berman, CEO of enVVeno Medical. "We have been busy working on our strategic plans for 2026, the details of which will become evident in the coming weeks, and regaining compliance with listing requirements for The Nasdaq Capital Market positions the Company to execute those plans."

At the effective time of the Reverse Stock Split, every thirty-five (35) shares of NVNO common stock issued and outstanding will be combined into one (1) share of common stock issued and outstanding, with no change to the par value of $0.00001 per share. This will reduce the Company's outstanding common stock from approximately 22.9 million shares to approximately 655 thousand shares. The Company will not issue fractional shares as a result of the Reverse Stock Split and will instead pay cash for any fractional shares resulting from the reverse split. The shares and exercise prices, as applicable, underlying the Company's outstanding equity awards and warrants will also be adjusted accordingly.

The Company's transfer agent, Equiniti Trust Company, LLC, will provide stockholders of record holding certificates representing pre-split shares of the Company's common stock as of the effective date, a letter of transmittal providing instructions for the exchange of shares. Registered stockholders holding pre-split shares of the Company's common stock electronically in book-entry form are not required to take any action to receive post-split shares. Stockholders owning shares via a broker, bank, trust or other nominee will have their positions automatically adjusted to reflect the Reverse Stock Split, subject to such broker's particular processes, and will not be required to take any action in connection with the Reverse Stock Split.

Additional information regarding the Reverse Stock Split can be found in the Company's definitive proxy statement (Form DEF 14A) and revised definitive proxy statement filed with the U.S. Securities and Exchange Commission on October 30, 2025 and December 2, 2025, respectively. Equiniti can be reached by phone at (877) 248-6417 (toll free) or (718) 921-8317.

About enVVeno Medical Corporation
enVVeno Medical (NASDAQ:NVNO) is an Irvine, California-based, late clinical-stage medical device Company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of deep venous disease.

Cautionary Note on Forward-Looking Statements
This press release and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical Corporation (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements identified by words such as "projects," "may," "will," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," "potential" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results and timing may differ significantly from those set forth or implied in the forward-looking statements. Forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

INVESTOR CONTACT:
Jenene Thomas, JTC Team, LLC
NVNO@jtcir.com
(908) 824-0775

MEDIA CONTACT:
Glenn Silver, FINN Partners
Glenn.Silver@finnpartners.com
(973) 818-8198

SOURCE: enVVeno Medical Corporation

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the reverse stock split ratio for enVVeno Medical (NVNO)?

enVVeno Medical is executing a 1-for-35 reverse stock split.

When will NVNO's reverse stock split become effective and trade post-split?

The Reverse Stock Split is effective at 12:01 a.m. ET on January 20, 2026, and NVNO will trade post-split on January 20, 2026.

How many shares will enVVeno Medical have outstanding after the NVNO split?

Outstanding common stock will be reduced from approximately 22.9 million to approximately 655 thousand shares.

Will NVNO issue fractional shares after the reverse split?

No; the company will not issue fractional shares and will instead pay cash for any fractional amounts.

Was the NVNO reverse split approved by shareholders and when?

Yes; stockholders approved the Reverse Stock Split at the annual meeting on December 11, 2025.

Will NVNO’s equity awards and warrants change because of the reverse split?

Yes; the shares and exercise prices underlying outstanding equity awards and warrants will be adjusted accordingly.

What is the new CUSIP for enVVeno Medical after the NVNO reverse split?

The new CUSIP for post-split NVNO common stock is 29415J205.